Back to Search
Start Over
COVID-19 Infection: Targeting Possibilities for Treatment
- Source :
- Critical Reviews™ in Therapeutic Drug Carrier Systems. 38:75-115
- Publication Year :
- 2021
- Publisher :
- Begell House, 2021.
-
Abstract
- The outbreak of novel coronavirus (nCoV) or severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in December 2019 in Wuhan, China, has posed an international public health emergency worldwide and forced people to be confined in their homes. This virus is of high-risk category and is declared a pandemic by the World Health Organization (WHO). The worldwide researchers and various health professionals are working together to determine the best way to stop its spread or halt this virus's spread and circumvent this pandemic condition threatening millions of human lives. The absence of definitive treatment is possible to explore to reduce virus infection and enhance patient recovery. Along with off-label medicines, plasma therapy, vaccines, the researchers exploit the various plants/herbs and their constituents to effectively treat nCoV infection. The present study aimed to present brief and most informative salient features of the numerous facts regarding the SARS-CoV-2, including the structure, genomic sequence, recent mutation, targeting possibility, and various hurdles in research progress, and off-labeled drugs, convalescent plasma therapy, vaccine and plants/herbs for the treatment of coronavirus disease-2019 (COVID-19). Results showed that off-labeled drugs such as hydroxychloroquine, dexamethasone, tocilizumab, antiviral drug (remdesivir, favipiravir), etc., give positive results and approved for use or approved for restricted use in some countries like India. Future research should focus on these possibilities that may allow the development of an effective treatment for COVID-19.
- Subjects :
- medicine.medical_specialty
COVID-19 Vaccines
medicine.drug_class
Favipiravir
medicine.disease_cause
Antiviral Agents
chemistry.chemical_compound
Tocilizumab
Pandemic
medicine
Humans
Molecular Targeted Therapy
Intensive care medicine
Pandemics
Coronavirus
Viral Structural Proteins
Clinical Trials as Topic
Plant Extracts
SARS-CoV-2
business.industry
COVID-19
Outbreak
International health
Hydroxychloroquine
Off-Label Use
General Medicine
COVID-19 Drug Treatment
Treatment Outcome
chemistry
Mutation
Drug Therapy, Combination
Angiotensin-Converting Enzyme 2
Antiviral drug
business
medicine.drug
Subjects
Details
- ISSN :
- 07434863
- Volume :
- 38
- Database :
- OpenAIRE
- Journal :
- Critical Reviews™ in Therapeutic Drug Carrier Systems
- Accession number :
- edsair.doi.dedup.....2200056875697834325a72e0ce80006b